Jeffrey Lieberman M.D

Fast Company | Wall Street is embracing the psychedelic industry—and it’s causing a culture clash

Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction, and other mental health conditions.

While psychedelics are still illegal under federal law, companies are jostling to try and patent key ingredients found in magic mushrooms, ayahuasca, and other substances that have been used underground for decades or—in some cases—for millennia by indigenous cultures.